Smart Immune Partners with CELLforCURE for Production Growth
Smart Immune, a dedicated biotechnology company focusing on innovative cell therapies, alongside CELLforCURE by SEQENS, a renowned Contract Development and Manufacturing Organization (CDMO), have joined forces to elevate the production capabilities of SMART101. This exciting collaboration centers on an advanced therapy currently undergoing Phase I/II trials aimed at treating patients with acute leukemia and primary immunodeficiencies.
Boosting Production Capabilities
The strategic partnership between these two entities will significantly enhance Smart Immune's existing capabilities established at the MEARY Center for Cell and Gene Therapy. This collaboration is pivotal as patient inclusions are poised to accelerate in the coming year. Notably, the partnership will support the manufacturing of SMART101 for the ReSET trials which focus on primary immune deficiencies and hematological malignancies following transplant procedures, along with initiating new trials targeting solid tumors.
With CELLforCURE's strong reputation and extensive experience in commercial manufacturing, Smart Immune is well-positioned for success during this crucial phase of development. This collaboration is seen as an essential step in enriching the ProTcell platform, the cornerstone of Smart Immune's therapeutic approach.
Refining the Manufacturing Process
As part of their partnership, an updated intermediate manufacturing process is in the works at the MEARY Centre. This initiative aims to bridge the existing gap between clinical production methodologies and future fully automated systems. This upcoming evolution is anticipated to streamline cell selection processes while scaling up production in alignment with the expected v2.0 requirements. Moreover, key steps will be semi-automated, including the integration of mini-bioreactor-based production techniques, which will greatly enhance efficiency.
Improving Access for Patients
Karine Rossignol, CEO of Smart Immune, heralded this collaboration as a monumental advancement in delivering innovative cell therapies to a broader patient population. Rossignol stated, "This partnership establishes a robust manufacturing framework that meets our increasing clinical program demands and future commercialization needs." This commitment to innovation resonates firmly with both organizations as they strive to improve patient outcomes.
Pierre-Noël Lirsac, President of CELLforCURE, expressed pride in the partnership, noting their extensive historical expertise in CDMO services. He remarked, "We will leverage our capabilities to ensure the effective manufacturing of SMART101 clinical batches." This sentiment is echoed by Pierre Heimendinger, CTO of Smart Immune, who highlighted the enhanced manufacturing process, which enables rapid sterility testing, leading to a significant reduction in vein-to-vein time for patients.
Strategic Manufacturing in Europe
The selection of CELLforCURE indicates Smart Immune's commitment to maintaining high standards of production excellence in Europe. This strategic choice aligns with an established framework at the MEARY Center located in Saint-Louis Hospital. The partnership underscores a resolute commitment to utilize local European production expertise in developing advanced therapy frameworks.
The SEQENS Group's investment in this collaboration further emphasizes its mission to bolster essential healthcare capabilities across Europe, ensuring the availability of cutting-edge therapeutic options.
About CELLforCURE and SEQENS
CELLforCURE, operating under SEQENS, is an authorized CDMO that specializes in the production of Advanced Therapy Medical Products (ATMPs). The organization supports a seamless transition from early development stages to commercial manufacturing, ensuring high-quality cell therapies are accessible to those who need them.
About Smart Immune
Smart Immune is dedicated to revolutionizing treatment approaches for patients battling cancer and infections. By advancing the ProTcell platform, the company crafts innovative therapies that aim to significantly improve health outcomes for those affected. With their primary asset, SMART101, actively undergoing clinical trials, Smart Immune stands at the forefront of pioneering treatments in hematology and immuno-oncology.
Frequently Asked Questions
What is the collaboration between Smart Immune and CELLforCURE about?
The collaboration focuses on enhancing the production capabilities of SMART101, an innovative therapy for acute leukemia and primary immunodeficiencies.
What role does CELLforCURE play in this partnership?
CELLforCURE will leverage its expertise in commercial manufacturing to produce clinical batches of SMART101 efficiently and effectively.
What improvements are expected in the manufacturing process?
The collaboration aims to transition the production process towards more automated and efficient methodologies, including semi-automated steps and mini-bioreactor integration.
How does this collaboration benefit patient access to treatments?
This partnership is aimed at accelerating the production of therapies, thereby improving patient access to innovative treatments for serious conditions quicker than previously possible.
What is the significance of this manufacturing choice in Europe?
The decision to manufacture in Europe reinforces Smart Immune's commitment to maintaining high-quality production standards and utilizing local expertise in developing advanced therapies.
